On April 27[th] CMO Peter Michael Vestlev will present at the AACR Virtual Annual Meeting. The presentation is a 5 minutes video entitled “Clinical phase II study of SCO-101 – an inhibitor of SRPK1 and ABCG2 – restoring sensitivity to FOLFIRI in metastatic FOLFIRI resistant colorectal cancer patients”
The AACR Virtual Annual Meeting will feature a selection of high-impact proffered paper presentations. The program will include a number of clinical trial plenary sessions featuring more than 30 oral presentations along with perspectives on the science behind the clinical trials by experts discussants; clinical trial poster sessions; several minisymposia that showcase basic and translational science; and three New Drugs on the Horizon symposia that include first disclosures of innovative small molecules and biologics that have recently entered phase I clinical trials.
The presentation will be a part of the Session VPO.CT07.02 – Phase II Trials in Progress and the abstract is number 10343.
The presentation will be at available from 9:00 a.m. – 6:00 p.m. (U.S. EDT).
The abstract will be posted online at the AACR webpage at 12:01 a.m. EDT (U.S.) on Monday, April 27.
The Virtual Meeting will be available free to everyone, although attendees will be asked to register to participate.